arrow
R

Róbert Královics

Medical University of Vienna
H指数:61
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)

早期真性红细胞增多症患者的无事件生存率与对alfa-2b或羟基脲/最佳可用疗法 (PROUD-PV/CONTINUATION-PV) 的分子反应相关

2025-05-030
OAAI
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms
2023-03-094
OA
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
2022-01-2114
OAAI
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
2022-01-044
OAAI
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
2021-10-2919
OAAI
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

血液学2021中的精准医学: 定义、工具、观点和开放性问题

2021-03-017
OAAI
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
2020-10-205
OAAI
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
2020-03-01232
OAAI
MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation

MTHFD1与BRD4的相互作用将叶酸代谢与转录调控联系起来

2019-05-2764
OAAI
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia

STAT5A的高激活驱动外周T细胞淋巴瘤和白血病

2019-05-2335
OAAI
International external quality assurance of JAK2 V617F quantification
2018-12-087
OAAI